The study was performed in accordance with good clinical practice and the ethical principles that have their origin in the Declaration of Helsinki. The protocol was approved by the appropriate institutional review boards or ethics committees, and the subjects gave written, informed consent to participate. Patients Eligible subjects who gave consent were randomly assigned in a 1:1 ratio to the two treatment groups. Women were eligible to enroll selleck in the study if they were at least 50 years of age, ambulatory, in generally good health, postmenopausal (at least 5 years since last menses),
had at least three vertebral bodies in the lumbar spine (L1 to L4) that were evaluable by densitometry (i.e., without fracture or degenerative disease), and had a lumbar spine BMD T-score of less than −2.5 or a T-score of less than −2.0 with at least one prevalent vertebral fracture (T4 to L4). Specific details of the inclusion criteria and methods have been previously published [6]. Treatments Subjects received oral risedronate Dinaciclib concentration 5-mg daily or 150-mg once a month (i.e., a single 150-mg tablet on the same calendar day each month, followed by a placebo tablet daily for the rest of the month). All tablets were identical in appearance and Ilomastat in vitro supplied in identical blister cards. Tablets were taken on an empty stomach in the morning at least 30 min before the first food or drink of the
day, with at least 4 oz of plain water. Subjects were instructed to remain in an upright position for at least 30 min after dosing. Subjects were considered compliant if they took at least 80 % of the study tablets. Calcium (1,000-mg/day) and vitamin D (400–500 IU/day) were supplied to all subjects, although they were allowed to take up to 1,000 IU/day of vitamin D. These supplements were taken with a meal
other than breakfast and not with the study medication. Efficacy assessments Dual x-ray absorptiometry (DXA) measurements of the lumbar spine and proximal femur were obtained at baseline and after 6, 12, and 24 months using instruments manufactured by Lunar Corporation (General Electric, Madison, WI, USA) or Hologic (Waltham, MA, USA). DXA scans collected at the clinical sites were sent to a central facility for quality control and analysis (Synarc, Copenhagen/Hamburg). Lateral thoracic and lumbar spine radiographs collected at screening and at 12 and 24 months were analyzed for Sorafenib vertebral fractures by semi-quantitative analysis [7] at a central radiology site (Synarc, Copenhagen/Hamburg). Biochemical markers of bone turnover were assessed at 3, 6, 12, and 24 months. Serum bone-specific alkaline phosphatase (BALP) was measured using an immunochemiluminescence assay on an automatic analyzer (Ostase, Access, Beckman Coulter, LaBrea, CA, USA). The intra- and interassay coefficients of variation for this measurement were less than 4 and 10 %, respectively. The detection limit of the test was 0.07 ng/mL, and the limit of quantitation was 0.